{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:14:08Z","timestamp":1780982048345,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R25CA092203"],"award-info":[{"award-number":["R25CA092203"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ygyno.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T19:34:51Z","timestamp":1466624091000},"page":"248-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["\u201cCarcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities\u201d"],"prefix":"10.1016","volume":"142","author":[{"given":"J. Alejandro","family":"Rauh-Hain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.06.003_bb0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1525-1438.2006.00760.x","article-title":"Current management of ovarian carcinosarcoma","volume":"17","author":"Mano","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2011.02.023","article-title":"Carcinosarcoma of the ovary: a case\u2013control study","volume":"121","author":"Rauh-Hain","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"9 Suppl. 3","key":"10.1016\/j.ygyno.2016.06.003_bb0015","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma","volume":"24","author":"Berton-Rigaud","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2011.12.418","article-title":"Carcinosarcoma of the ovary: a review of the literature","volume":"125","author":"del Carmen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006246.pub2","article-title":"Chemotherapy and\/or radiotherapy in combination with surgery for ovarian carcinosarcoma","volume":"2","author":"Shylasree","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.ygyno.2016.06.003_bb0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/OGX.0b013e3181b8aff3","article-title":"Carcinosarcoma of the ovary a review","volume":"64","author":"Cantrell","year":"2009","journal-title":"Obstet. Gynecol. Surv."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2004.09.051","article-title":"Clinicopathological features of ovarian carcinosarcomas: a single institution experience","volume":"96","author":"Zorzou","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/94.1.1","article-title":"The immunohistochemical profile of malignant mixed m\u00fcllerian tumor. Overlap with endometrial adenocarcinoma","volume":"94","author":"Meis","year":"1990","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0045","first-page":"109","article-title":"Carcinosarcoma of the Ovary","year":"2015"},{"issue":"5","key":"10.1016\/j.ygyno.2016.06.003_bb0050","doi-asserted-by":"crossref","first-page":"550","DOI":"10.6004\/jnccn.2009.0037","article-title":"Carcinosarcomas (malignant mixed M\u00fcllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics","volume":"7","author":"Kernochan","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.pgp.0000092134.88121.56","article-title":"Carcinosarcomas (malignant Mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis","volume":"22","author":"Jin","year":"2003","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-007-0557-6","article-title":"Molecular genetic aberration of ovarian and uterine carcinosarcomas - a CGH and FISH study","volume":"452","author":"Schipf","year":"2008","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2010.11.039","article-title":"Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin","volume":"121","author":"Growdon","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0070","first-page":"114","article-title":"Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity","volume":"60","author":"Fujii","year":"2000","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","article-title":"Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis","volume":"131","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2013.06.034","article-title":"Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome","volume":"131","author":"George","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0085","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4","article-title":"Primary ovarian sarcoma - analysis of prognostic variables and the role of surgical cytoreduction","volume":"82","author":"Sood","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0090","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjc.6600770","article-title":"Carcinosarcoma of the ovary","volume":"88","author":"Harris","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0095","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.annonc.a059312","article-title":"Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients","volume":"8","author":"Chang","year":"1995","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2016.06.003_bb0100","first-page":"660","article-title":"Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases","volume":"80","author":"Barakat","year":"1992","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1046\/j.0004-8666.2003.00003.x","article-title":"Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy","volume":"43","author":"Inthasorn","year":"2003","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0110","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0090-8258(89)80038-1","article-title":"Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas","volume":"32","author":"Terada","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0090-8258(90)90341-H","article-title":"Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin and cisplatin-based chemotherapy","volume":"37","author":"Plaxe","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2016.06.003_bb0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1006\/gyno.2002.6645","article-title":"Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary","volume":"85","author":"Duska","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2005.07.119","article-title":"Carcinosarcoma of the ovary - a case series","volume":"100","author":"Rutledge","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.06.003_bb0135","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2014.03.002","article-title":"Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma","volume":"133","author":"Doo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0140","first-page":"720","article-title":"Malignant mixed mesodermal tumor of the ovary: a report of 22 cases","volume":"65","author":"Dictor","year":"1985","journal-title":"Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.ygyno.2016.06.003_bb0145","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/1097-0142(19951001)76:7<1209::AID-CNCR2820760717>3.0.CO;2-V","article-title":"Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy","volume":"76","author":"Muntz","year":"1995","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2016.06.003_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2559.2000.01015.x","article-title":"Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases","volume":"37","author":"Ariyoshi","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1525-1438.2007.00919.x","article-title":"The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy","volume":"17","author":"Athavale","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0160","first-page":"118","article-title":"Mutation and overexpression of the P53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas","volume":"83","author":"Liu","year":"1994","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2004.09.051","article-title":"Clinicopathological features of ovarian carcinosarcomas: a single institution experience","volume":"96","author":"Zorzou","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0463.2008.00757.x","article-title":"Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas","volume":"116","author":"Nayha","year":"2008","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0175","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2559.1998.00425.x","volume":"32","author":"Jensen","year":"1998","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ygyno.2016.06.003_bb0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0090-8258(89)90632-X","article-title":"Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary","volume":"32","author":"Andersen","year":"1989","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2016.06.003_bb0185","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/gyno.1995.1248","article-title":"Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for ovarian mixed mullerian sarcoma: report of four cases","volume":"58","author":"Partsner","year":"1995","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2016.06.003_bb0190","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.20256","article-title":"Carcinosarcoma of the ovary: 19years of prospective data from a single center","volume":"100","author":"Brown","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2007.09.003","article-title":"Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum","volume":"108","author":"Cicin","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00000421-198602000-00007","article-title":"Adriamycin chemotherapy for malignant mixed mesodermal tumor of the ovary. A gynecologic oncology group study","volume":"9","author":"Morrow","year":"1986","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2004.01.007","article-title":"Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a gynecologic oncology group study","volume":"93","author":"Tate Thigpen","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2016.06.003_bb0210","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: treatment update","volume":"27","author":"Foley","year":"2013","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.ygyno.2016.06.003_bb0215","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/IGC.0b013e3181a8ef22","article-title":"Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma","volume":"19","author":"Barholtz-Sloan","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/gyno.1994.1081","article-title":"A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a gynecologic oncology group study","volume":"53","author":"Sutton","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0225","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemo-therapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2016.06.003_bb0230","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2016.06.003_bb0235","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1349-7006.2003.tb01389.x","article-title":"Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma","volume":"94","author":"Sawada","year":"2003","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2016.06.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126867","article-title":"Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft","volume":"10","author":"Glaser","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0250","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2015.08.002","article-title":"Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo","volume":"139","author":"Schwab","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2","volume":"32","author":"Nicoletti","year":"2015","journal-title":"Clin. Exp. Metastasis"},{"issue":"3","key":"10.1016\/j.ygyno.2016.06.003_bb0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2011.11.042","article-title":"A phase II study single agent of aflibercept (VEGF trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia","volume":"125","author":"Mackay","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2016.06.003_bb0270","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","article-title":"BRCAness: finding the Achilles heel in ovarian cancer","volume":"17","author":"Rigakos","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ygyno.2016.06.003_bb0275","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2016.04.025","article-title":"Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis","volume":"142","author":"Rauh-Hain","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0280","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2004.02.016","article-title":"Survival of women diagnosed with malignant mixed mullerian tumors of the ovary (OMMMT)","volume":"93","author":"Barholtz-Sloan","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0285","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0090-8258(84)90039-8","article-title":"A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: a gynecologic oncology group study","volume":"18","author":"Morrow","year":"1984","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0090-8258(87)90272-1","article-title":"Ovarian sarcoma","volume":"26","author":"Anderson","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0295","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ygyno.2007.01.037","article-title":"Carcinosarcoma of the ovary treated with platinum and taxane: the Memorial-Sloan Kettering Cancer Center experience","volume":"105","author":"Leiser","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.06.003_bb0300","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ygyno.2006.12.023","article-title":"A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary","volume":"105","author":"Crotzer","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1525-1438.1994.04030200.x","article-title":"Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital","volume":"4","author":"Prendiville","year":"1994","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.06.003_bb0310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/gyno.2000.5956","article-title":"Chemotherapy formalignant mixedmullerian tumors of the ovary","volume":"79","author":"Sit","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.06.003_bb0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1525-1438.2006.00281.x","article-title":"Malignant mixed mullerina tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy","volume":"16","author":"Mok","year":"2006","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816307715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816307715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T01:49:32Z","timestamp":1568080172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816307715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0090825816307715"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cCarcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities\u201d","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}